<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23298471</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-6362</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jan</Month>
                        <Day>08</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arthritis research &amp; therapy</Title>
                <ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>R6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/ar4134</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although the safety of celecoxib has been investigated, limited data are available on complications affecting the entire (upper and lower) gastrointestinal (GI) tract, with no patient-level pooled analyses of upper and lower GI outcomes available. We therefore evaluated the upper and lower GI safety of celecoxib by using patient-level data from randomized controlled trials (RCTs).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This patient-level pooled analysis included 52 prospective, randomized, double-blind parallel-group studies from the Celecoxib Clinical Database. Each study had a planned duration of continuous treatment with celecoxib or a nonselective nonsteroidal antiinflammatory drug (nsNSAID), rofecoxib, or the placebo comparator arm for at least 4 weeks. All studies with final reports completed by 1 October 2007 were included. The primary end point was the combined incidence of clinically significant upper and lower GI events (CSULGIEs). An independent blinded committee reviewed and adjudicated all end points by using predefined criteria and all available reported adverse events, laboratory data, and case narratives. All doses of celecoxib and all doses of all nsNSAIDs were pooled for analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The pooled analysis involved 51,048 patients; 28,614 were randomized to celecoxib; 15,278 to nsNSAIDs (including 3,248 patients taking naproxen, 2,640 taking ibuprofen, 8,066 taking diclofenac, 1,234 taking loxoprofen, and 90 taking ketoprofen); 5,827 to placebo and 1,329 to rofecoxib. The mean age was 60 years, and 65% were women. Data on 1,042 patients with potential GI events were reviewed for end-points adjudication; the adjudication committee confirmed 89 patients with CSULGIEs. The majority were in the celecoxib and nsNSAID groups (with raw incidence proportions of 37 (0.1%) and 40 (0.3%), respectively). The incidence rates were 0.3, 0.9 and 0.3 per 100 patient-years in the celecoxib, nsNSAID, and placebo groups, respectively. The time to incidence of CSULGIEs was significantly longer with celecoxib than with nsNSAIDs (P=0.0004).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">When compared with nsNSAIDs, celecoxib is associated with a significantly lower risk of all clinically significant GI events throughout the entire GI tract. This pooled analysis of 52 RCTs significantly advances the understanding of the upper and lower GI safety profile of celecoxib and its potential benefits to patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makinson</LastName>
                    <ForeName>Geoffrey</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chunming</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>01</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Arthritis Res Ther</MedlineTA>
            <NlmUniqueID>101154438</NlmUniqueID>
            <ISSNLinking>1478-6354</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JCX84Q7J1L</RegistryNumber>
                <NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D052246" MajorTopicYN="N">Cyclooxygenase 2 Inhibitors</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>01</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23298471</ArticleId>
            <ArticleId IdType="pii">ar4134</ArticleId>
            <ArticleId IdType="doi">10.1186/ar4134</ArticleId>
            <ArticleId IdType="pmc">PMC3672676</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Pain. 2000 Apr;85(3):415-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10781914</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Gastroenterol. 2013 Mar;108(3):392-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23399552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Pract. 2001 May;55(4):240-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11406908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 2002 Sep 21;325(7365):619</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12242171</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 2002 Sep 21;325(7365):624</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12242172</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2003 Feb;124(2):288-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12557133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1984 Nov 24;2(8413):1171-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6150232</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1992 Sep 10;327(11):749-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1501650</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1994 Mar 26;343(8900):769-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7907735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Control Clin Trials. 1997 Dec;18(6):568-79; discussion 661-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9408719</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pain. 1998 Dec;78(3):209-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9870574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1999 Jan 23;353(9149):307-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9929039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arthritis Res Ther. 2005;7(3):R644-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15899051</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 2006 Mar;119(3):255-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16490472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 2006 Jun 3;332(7553):1302-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16740558</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Oct 4;296(13):1633-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16968831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17451567</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Gastroenterol Hepatol. 2007 Jul;5(7):818-28, 828.e1-5; quiz 768</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17556027</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arthritis Rheum. 2008 Aug 15;59(8):1097-104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18668605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Clin North Am. 2009 Jun;38(2):333-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19446262</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacotherapy. 2009 Dec;29(12):1397-407</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19947799</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Rheumatol. 2010 Jan;37(1):167-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19884267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Rheum Dis. 2010 Feb;69(2):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19364730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Jul 17;376(9736):173-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20638563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Gastroenterol. 2010 Nov;26(6):611-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20948372</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2011 Sep;8(9):e1001098</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21980265</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2000 Sep 13;284(10):1247-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10979111</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
